The credibility of our findings, unique to the prescription of MRAs, is strengthened by the substantial consistency with studies regarding physician barriers to ACE inhibitor and beta‐blocker use in HF patients.20, 22 We addressed our topic from a variety of complementary methods, including a survey, focus groups, and member check interviews, to arrive at our conclusions. This evidence concerns the gene ACE and hydrops fetalis.